Repros Therapeutics (RPRX) Earning Somewhat Favorable Press Coverage, Report Finds
News coverage about Repros Therapeutics (NASDAQ:RPRX) has trended somewhat positive recently, according to Accern. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Repros Therapeutics earned a news sentiment score of 0.22 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 44.9069499167333 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the media headlines that may have impacted Accern Sentiment’s analysis:
- Will Shareholder Love To Invest in This Stock?: Repros Therapeutics Inc (NASDAQ: RPRX) – Alpha Beta Stock (alphabetastock.com)
- Repros Therapeutics (RPRX) Has Stock More Room to Run – ExpertGazette (expertgazette.com)
- BRIEF-MMCAP International Reports An 8.48 Pct Passive Stake In Repros Therapeutics (RPRX) (markets.businessinsider.com)
- Repros Therapeutics Inc. (NASDAQ:RPRX) – Is P/E & PEG The Same Thing – Nasdaq Journal (press release) (nasdaqjournal.com)
- Hot Stock’s Highlights: Repros Therapeutics Inc (NASDAQ: RPRX) – Alpha Beta Stock (alphabetastock.com)
Repros Therapeutics (RPRX) remained flat at $$0.66 during mid-day trading on Friday. The company’s stock had a trading volume of 314,100 shares, compared to its average volume of 749,900. The company has a market cap of $26.34, a price-to-earnings ratio of -1.32 and a beta of 0.45. Repros Therapeutics has a 1-year low of $0.26 and a 1-year high of $1.55.
Repros Therapeutics (NASDAQ:RPRX) last posted its earnings results on Monday, November 13th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.24. The company had revenue of $0.30 million during the quarter. Repros Therapeutics had a negative return on equity of 894.22% and a negative net margin of 4,242.73%.
Separately, S&P Equity Research cut their price target on Repros Therapeutics from $0.49 to $0.39 in a report on Monday, November 20th.
TRADEMARK VIOLATION WARNING: This piece was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.watchlistnews.com/repros-therapeutics-rprx-earning-somewhat-favorable-press-coverage-report-finds/1795592.html.
Repros Therapeutics Company Profile
Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.
Receive News & Ratings for Repros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.